USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ARGINOX PHARMACEUTICALS, INC.
City: MENLO PARK
State: CA
Zip+4: 94025
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (650) 324-5150

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $592,185.00 3

Award List:

NOS Inhibitor Therapy for Cardiogenic Shock

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven S. Gross
Award Amount: $271,044.00
Abstract:
DESCRIPTION (provided by applicant): This is a Fast-track Phase I application from ArgiNOx Inc. to develop a novel pharmacotherapy that may save lives of tens of thousands of patients that develop cardiogenic shock each year in the USA. Cardiogenic shock is lethal in an estimated 60 percent of… More

Therapy for Improving Vascular Function in Diabetes

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul B. Lane
Award Amount: $128,203.00
Abstract:
DESCRIPTION (provided by applicant): ArgiNOx is a recently-formed Wisconsin-based biotech startup that seeks to develop novel therapies for cardiovascular and inflammatory conditions resulting from insufficient or excess nitric oxide (NO). In the cardiovascular system, NO is an endogenous… More

Use of NOS inhibitor to expand hematopoietic stem cells

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter Krasnov
Award Amount: $192,938.00
Abstract:
DESCRIPTION (provided by applicant): Hematopoietic cell-supported therapy is employed for a broad spectrum of malignancies and hematological disease. However, the approach is limited by the availability of hematopoietic stem cells; thus, the possibility of expanding the number of hematopoietic stem… More